[ad_1]

The offices of Novo Nordisk in Copenhagen, Denmark.

The places of work of Novo Nordisk in Copenhagen, Denmark.
Photograph: Tom Little (Reuters)

Novo Nordisk’s weight reduction medicine Ozempic and Wegovy are fashionable, and highly effective. Like, actually fashionable. So fashionable that they’re raising the GDP of the company’s native Denmark. So fashionable that food company executives are fearfully calling Novo Nordisk CEO Lars Fruergaard Jorgensen to ask for recommendation as a result of sufferers don’t wish to eat. And now the corporate is teasing a tablet that is perhaps twice as highly effective.

Novo Nordisk informed traders that an early-stage drug trial discovered that an oral model of the drug amycretin results in customers dropping 13% of their physique weight after 12 weeks of remedy. Novo Nordisk inventory was up greater than 8% to a report excessive in Monday morning buying and selling, at about $135 per share.

Learn extra: 3 food and drink chains set to gain from Ozempic’s rise

The research concerned giving a pill code-named NNC0487-0111 to overweight Japanese males at a clinic in Fukoka, Japan, and remains to be ongoing. Part 1 trials just like the one which produced the outcomes that has Novo Nordisk bragging are very early in what may very well be a years-long course of and far smaller than Part II, III, and IV trials, — that are a lot bigger and will result in completely different outcomes as various factors are thought of.

But when issues pan out, the brand new treatment would impact weight reduction twice as shortly as Wegovy, whose sufferers lose 6% of their weight in 12 weeks. That it’s a tablet may additionally make it extra palatable than Ozempic and Wegovy, which each have to be injected.

Reuters studies that Wednesday’s inventory transfer was sufficient to make Novo Nordisk, whose shares have already climbed 33% this 12 months, more valuable than Tesla and the 12th-most valuable company on the planet.

[ad_2]

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *